Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study
Alexandre Bazinet(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Faezeh Darbaniyan(The University of Texas MD Anderson Cancer Center), Guillermo Montalban‐Bravo(The University of Texas MD Anderson Cancer Center), Kelly S. Chien, Bailey Mirabella(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Musa Yılmaz(The University of Texas MD Anderson Cancer Center), Koichi Takahashi(The University of Texas MD Anderson Cancer Center), Simona Colla(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Rashmi Kanagal‐Shamanna(The University of Texas MD Anderson Cancer Center), Yesid Alvarado(The University of Texas MD Anderson Cancer Center), Irene Gañán‐Gómez(The University of Texas MD Anderson Cancer Center), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Lucia Masárová(The University of Texas MD Anderson Cancer Center), Deborah McCue(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Wei Qiao(Prince Philip Dental Hospital), Maro Ohanian(The University of Texas MD Anderson Cancer Center)
Cited by 85
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Telomere dysfunction induces metabolic and mitochondrial compromise
|Nature|2011|1.3k